http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104610435-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate | 2015-01-26^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-12-19^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-12-19^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-104610435-B |
titleOfInvention | An anti-tumor polypeptide capable of targeting and inhibiting ERK signaling pathway and its application |
abstract | The invention relates to an anti-tumor polypeptide capable of targeting and inhibiting ERK signaling pathway and application thereof. The present invention constructs a small-molecule polypeptide that targets and inhibits the ERK signaling pathway, and a series of biological experiments prove that the small-molecule polypeptide can effectively overcome the PI3K/ The drug resistance of AKT inhibitors or paclitaxel drugs in the course of anti-tumor treatment has a significant synergistic anti-tumor effect. Since the ERK signaling pathway exists in a variety of tumors, it is an important signaling pathway that promotes cell growth and tumorigenesis and development. Therefore, the small molecule polypeptide can be used for the treatment of such tumors, preferably in combination with PI3K/AKT inhibitors or paclitaxel drugs. |
priorityDate | 2015-01-26^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 87 of 87.